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generation antipsychotics (SGAs) were prescribed regardless of mono-therapy or 
combination therapy. Risperidone [n= 17 (56.7%)] was most frequently prescribed, 
followed by aripiprazole [n= 7 (23.3%)] and olanzapine [n= 5 (16.7%)]. Haloperidol was 
the predominant first generation antipsychotic (FGA) prescribed [n= 3(10%)]. Of the 
patients on combination therapy [n= 12], most [n= 10 (83.3%)] were on combination 
of two or more SGAs. A majority [n= 18(60%)] of the patients had an unchanged 
outcome at the time of discharge. ConClusions: The results of the study indicate 
that the therapy prescribed does not meet the clinical goals for the patients. A larger 
study is required to assess the prescription patterns and the predictors of outcomes 
among schizophrenics in the Indian population.
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objeCtives: The objective of this study was to determine the medication utiliza-
tion rates of stimulant, antidepressant, and antipsychotic medications during the 
period 2002-2012 in Texas Medicaid children aged 0 to 3 years old. Methods: Texas 
Medicaid prescription claims data from 2002 to 2012 were analyzed for patients 
who were 3 years old or younger. Specifically, stimulant, antidepressant, and antip-
sychotic prescription claims were assessed to determine trends by age and gen-
der. Results: The number of Texas Medicaid patients 3 years old and younger 
ranged from about 830,000 in 2002 to 1.3 million in 2012. From 2002 to 2012, the 
percent of children 3 years old and under prescribed stimulants increased from 
0.10% to 0.11% (highest year 2011 at 0.14%). For antidepressants, there was also an 
increase from 0.02% to 0.03% (highest year 2011 at 0.04%). In contrast, the percent 
of antipsychotic users decreased from 0.02% to less than 0.01% (highest year 2004 
at 0.02%). On average, over the 10-year period, the majority of utilizers were male 
(73.6% stimulants, 69.4% antidepressants, and 74.6% antipsychotics), and percent-
ages were similar from year to year. Three-year-olds represented the majority of 
medication users for each medication category, where they constituted more than 
75.0% of all users, at any point from 2002 to 2012. For patients 2 years old or younger, 
the stimulant utilization rate followed a generally steady decrease over the 10-year 
period, while the antipsychotic and antidepressant utilization rates increased from 
2002, peaked (around 2006 and 2010, respectively), and then decreased thereaf-
ter. ConClusions: The use of stimulant and antidepressant medications in Texas 
Medicaid children three years old and younger increased from 2002 to 2011 but then 
decreased in 2012. The use of antipsychotic medications in this age group peaked 
in 2004 and, overall, has been decreasing since then.
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objeCtives: Aripiprazole and risperidone are the only two FDA-approved drugs 
for treating autism. No study has looked at their actual use and their costs in real-
world settings. This will be the first study to examine the actual use of aripiprazole 
and risperidone in children with autism using insurance claims data. Methods: 
Nationwide 2008-2010 insurance claims data from the MarketScan research data-
base were used. Privately insured children with autistic spectrum disorders (ASD) 
were identified using diagnosis codes. Costs were measured as what insurance 
companies paid. Results: Though aripiprazole became the second approved antip-
sychotic drug for autism in 2009 after risperidone in 2002, the rate of aripiprazole 
use in 2010 (30%) barely increased from that in 2008 (27%) before the approval, 
which nevertheless was a huge jump from a rate of less than 5% in 2003 reported in 
another study. The rate of risperidone use (47%) was not affected after the approval 
of aripiprazole. The first generic formulation of risperidone was approved in mid-
2008, and generic risperidone use instantly went from zero to 50% within one month, 
reaching 90% by mid-2009. The average aripiprazole cost per child increased from 
$2986 in 2008 to $3534 in 2010, whereas the average risperidone cost decreased from 
$1481 in 2008 to $715 in 2010 due to use of the generic formulation. ConClusions: 
Because use of aripiprazole only minimally increased after approval suggests that 
the market for aripiprazole in autism may have been close to saturation before 
approval due to off-label use. In contrast, patients and clinicians responded imme-
diately to the debut of generic risperidone by switching to it from the same branded 
drug, but they did not switch from the more expensive branded aripiprazole to 
generic risperidone, even though the literature suggests similar efficacy and safety 
of the two drugs for autism.
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objeCtives: The objective of this study was to assess the treatment patterns 
of long-acting injectable antipsychotics (LAI-AP), notably in terms of treatment 
persistence and compliance, in a real life setting, using the provincial pub-
lic drug reimbursement program database of the Régie de l’assurance maladie du 
Québec(RAMQ). Methods: Patients with a diagnosis of schizophrenia/schizoaf-
fective disorder, who were incident users (no use in the previous 12 months) of a 
LAI-AP prescribed between January 1st 2008 and March 31st2012, at least 20 years 
old, and with continuous enrolment in the database during the study period were 
selected. Concomitant use of oral antipsychotics and treatment adherence with 
LAI-AP were analyzed. Persistence was estimated in terms of treatment duration. 
The study objective is to measure the impact of state PDMP characteristics on the 
dispensing of opioids and benzodiazepines to Medicaid beneficiaries. Methods: 
Medicaid dispensing and reimbursement data for each state (1990-2011) was 
obtained from the Medicaid Drug Rebate Program. Opioid and benzodiazepine pre-
scriptions dispensed were isolated from the data and standardized to morphine 
milligram equivalents (MMEs) and diazepam milligram equivalents (DMEs), respec-
tively. Data was merged with state PDMP characteristics obtained from the National 
Alliance of Model State Drug Laws and several potential explanatory variables were 
identified; including, operational program, compulsory provider participation, inter-
state data sharing, and proactive notification of potential abuse. A random effects 
model using GLS regression was employed to generate estimates of the impact of 
state PDMP characteristics over time on MMEs dispensed of Schedule II opioids 
(CII), dispensing of Schedule III opioids (CIII), and DMEs of benzodiazepines. MMEs, 
DMEs, and Medicaid reimbursement dollars per MME dispensed were log trans-
formed. Results: States with operational PDMPs dispensed on average 0.29 fewer 
logged MMEs of CII opioids (p< 0.05). States with PDMPs housed in law enforcement 
agencies dispensed 0.11 more logged MMEs of CII opioids (p< 0.05) on average and a 
1-unit increase in Medicaid reimbursement resulted in 0.39 more logged MMEs of 
CII opioids dispensed (p< 0.001). States with PDMP interstate data sharing dispensed 
0.11 more logged MMEs of CII opioids (p< 0.05). Results for CIII opioids and benzo-
diazepines were similar. ConClusions: States with operational PDMPs dispense 
fewer CII and CIII opioids, and benzodiazepines, to Medicaid patients. The amount 
of Medicaid reimbursement and data sharing with other states is associated with 
increased dispensing, but compulsory PDMP use and proactive reporting to health 
providers were not found to impact dispensing.
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objeCtives: Many state Medicaid programs have implemented restrictive formu-
lary policies designed to reduce prescription drug spending. However, restrictions 
limiting access to antidepressants could disrupt therapy for patients with major 
depressive disorder (MDD). This study’s objective is to examine the effect of for-
mulary restrictions on state spending and MDD patient outcomes. Methods: We 
used data on patient outcomes from 24 state Medicaid programs from 2001-2008. 
Outcome variables included MDD-related hospitalizations and inpatient, pharmacy 
and total spending. National data on employment and social program participa-
tion for Medicaid patients, including Social Security Disability Insurance (SSDI) and 
Supplemental Security Income (SSI) were collected from the American Community 
Survey (ACS) for 2008-2011. We linked these data to information on prior authoriza-
tion and step therapy targeting antidepressants use in Medicaid by state and year. 
We used regression to identify associative effects of state policies on outcomes 
conditional on patient characteristics. Results: Prior authorization was associated 
with a 5.7% increase in the annual, per-patient rate of MDD-related hospitaliza-
tions (p= 0.048); prior authorization and step therapy combined were associated 
with a 16.6% increase (p= 0.075). Inpatient expenditures also increased for MDD 
patients exposed to formulary restrictions on antidepressants: expenditures were 
5.8% higher (p= 0.369) for patients exposed to prior authorization alone and 18.4% 
higher (p= 0.014) for those exposed to both prior authorization and step therapy. 
There was no statistically significant relationship between formulary restrictions 
and either pharmacy spending or total spending. Prior authorization was associ-
ated with a 1.8% (p< 0.001) decrease in labor force participation among Medicaid 
patients. There was no significant association with SSI or SSDI receipt, but prior 
authorization was associated with increased receipt of other public assistance 
(p< 0.001). ConClusions: Formulary restrictions on antidepressants in Medicaid 
are not associated with lower spending for patients with MDD, and may be associ-
ated with worse health outcomes and reduced labor force participation.
PMH79
PrescriPtion Pattern of antiPsYcHotics aMong scHizoPHrenia 
Patients in an indian PsYcHiatric HosPital
Sudhapalli V.1, Sudhapalli P.2, Naik A.N.3, Mylapuram R.4, Bhandary V.5, Devaramane V.5, 
Balkrishnan R.6
1Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka, India, 
2The University of Texas at Austin, College of Pharmacy, Austin, TX, USA, 3Manipal College of 
Pharmaceutical Sciences, manipal, karnataka, India, 4Medeka Health Private Ltd., Bangalore, 
India, 5Dr. A V Baliga Memorial Hospital, Udupi, India, 6University of Michigan, Ann Arbor, MI, 
USA
objeCtives: The objective of this study was to describe the prescription pattern 
of antipsychotics among schizophrenia patients in a psychiatric hospital. The sec-
ondary objective was to describe the patient characteristics. Methods: A retro-
spective observational study was conducted from January, 2010 – January, 2011. All 
patients with a clinical diagnosis of schizophrenia who had been hospitalized during 
the study period were followed for one year post-hospitalization. Data on patient 
demographics, disease onset, clinical diagnosis, prescription medications and clini-
cal outcomes were obtained from the medical records. Outcomes were defined as 
per medical records as improved or unchanged upon discharge. Results: Thirty 
patients were hospitalized from January 2010 to January 2011 with a clinical diagno-
sis of schizophrenia. The population was unequally distributed in terms of gender. 
The mean age of the patients was 36.66 ± 9.24 years. Most patients [n = 17(53%)] had 
a family history of schizophrenia. Paranoid schizophrenia was the most common 
diagnosis among patients [n= 15 (50%)] followed by un-differentiated schizophre-
nia [n= 4(13.3%)], simple schizophrenia [n= 2 (13.3%)], catatonic schizophrenia [n= 2 
(13.3%)], hebephrenic schizophrenia [n= 2 (13.3%)]. Monotherapy with respect to 
antipsychotics was seen among a majority of the patients [n= 17(56.66%)]. Second 
